DEXterity of tolerogenic APCs

Authors

  • Katherine E. R. Stagliano,

    1. Laboratory of Molecular Immunoregulation, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA
    Search for more papers by this author
  • Joost J. Oppenheim

    Corresponding author
    • Laboratory of Molecular Immunoregulation, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA
    Search for more papers by this author

Full correspondence: Dr. Joost J. Oppenheim, Laboratory of Molecular Immunoregulation, Frederick National Laboratory for Cancer Research, National Cancer Institute, P.O. Box B, Bldg. 560, Rm. 21-89A, Frederick, MD 21702-1201, USA

Fax: +1-301-846-7042

e-mail: Oppenhei@ncifcrf.gov

See accompanying article by Zheng et al.

Abstract

A promising therapeutic approach for inducing tolerance in autoreactive T cells is the use of APCs such as DCs and macrophages. In this issue of the European Journal of Immunology, Zheng et al. [Eur. J. Immunol. 2013. 43: 219–227] study the concept of “tolerogenic adjuvants” to induce tolerance via vaccination. These authors have previously identified dexamethasone (Dex) as an effective “tolerogenic adjuvant” and, in this study, they have identified a population of peripheral macrophages that is enriched by Dex treatment and that mediates Dex's tolerogenic effect. In addition to performing a phenotypic characterization of this population, the authors noted an increase in serum levels of IL-10 and Treg cells after Dex treatment of mice. As discussed in this Commentary, by employing Dex as a tolerogenic adjuvant in the presence of relevant peptides, we may have a means of restoring specific immune tolerance in cases of autoimmune disease and allergy.

Ancillary